Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vatalanib

Next Previous
Drug Profile

Vatalanib

Alternative Names: CGP 79787; PTK 787; PTK/ZK; vatalanib-succinate; ZK 222584

Latest Information Update: 24 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma; Novartis
  • Developer Novartis
  • Class Antineoplastics; Phthalazines; Pyridazines; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Macrophage colony-stimulating factor receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Age-related macular degeneration; Colorectal cancer; Glioblastoma; Multiple myeloma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours

Most Recent Events

  • 29 May 2008 Novartis Pharmaceuticals in collaboration with Dana-Farber Cancer Institute terminates a phase I trial in Solid tumors in the US (NCT00358163)
  • 29 Apr 2008 Discontinued - Phase-I for Ovarian cancer in Germany (PO)
  • 29 Apr 2008 Discontinued - Phase-I for Renal cancer in Germany (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top